Platelet function testing in atherothrombotic disease: Steps forward in managing resistance to antiplatelet therapy

Kardiologia Polska

Volumn 66, Issue 4, 2008, Pages 478-479

  Grove, Erik L ^a   Hvas, Anne Mette ^a   Kristensen, Steen Dalby ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ARTERY THROMBOSIS; ATHEROTHROMBOTIC DISEASE; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR RISK; CELL ACTIVITY; CLINICAL STUDY; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG RESISTANCE; LABORATORY; NOTE; POPULATION; THROMBOCYTE; THROMBOCYTE FUNCTION;

EID: 53549085739     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-207.
3. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-9.
4. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8.
5. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-31.
6. Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5: 490-6.